Olema Selling General Administrative from 2010 to 2024
| OLMA Stock | USD 12.62 0.36 2.77% |
Selling General Administrative | First Reported 2010-12-31 | Previous Quarter 18.8 M | Current Value 13.3 M | Quarterly Volatility 8.8 M |
Check Olema Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Olema Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 6 M, Interest Income of 6 M or Depreciation And Amortization of 445.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.63. Olema financial statements analysis is a perfect complement when working with Olema Pharmaceuticals Valuation or Volatility modules.
Olema | Selling General Administrative |
Latest Olema Pharmaceuticals' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Olema Pharmaceuticals over the last few years. It is Olema Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Olema Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Olema Selling General Administrative Regression Statistics
| Arithmetic Mean | 5,928,388 | |
| Geometric Mean | 1,334,311 | |
| Coefficient Of Variation | 149.06 | |
| Mean Deviation | 7,387,584 | |
| Median | 386,000 | |
| Standard Deviation | 8,836,591 | |
| Sample Variance | 78.1T | |
| Range | 24.3M | |
| R-Value | 0.77 | |
| Mean Square Error | 34.5T | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | 1,517,885 | |
| Total Sum of Squares | 1093.2T |
Olema Selling General Administrative History
About Olema Pharmaceuticals Financial Statements
Olema Pharmaceuticals stakeholders use historical fundamental indicators, such as Olema Pharmaceuticals' Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Olema Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Olema Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Olema Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Olema Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 18.8 M | 13.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Olema Stock
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:Check out the analysis of Olema Pharmaceuticals Correlation against competitors. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (0.35) | Return On Equity (0.56) |
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.